An 8 Week Randomized, Placebo Controlled, Double-blind Study to Assess the Efficacy of Tiotropium Inhalation Capsules in Patients of African Descent With Chronic Obstructive Pulmonary Disease
- NCT00106821
- PHASE4
- INTERVENTIONAL
Last updated: 2013-11-01
Purpose of Trial
The purpose of this study is to look at the benefits of tiotropium, an approved drug for the treatment of bronchospasm associated with COPD (chronic obstructive pulmonary disease), in a population of patients with COPD who are of African American descent.
This study is for people with
Pulmonary Disease, Chronic Obstructive
Interventions being studied
Tiotropium Bromide Inhalation Powder
Inclusion Criteria:
* Male or female of African descent
* 40 years of age or older
* Diagnosis of COPD
* History of smoking at least one pack per day for at least 10 years
* Currently experiencing shortness of breath at least with exertion
Exclusion Criteria:
* Asthma
* Recent myocardial infarction or hospitalization for congestive heart failure
ELIGIBILITY
Gender: ALL
Age: 40+
Healthy Volunteers: No
19 Locations
Birmingham
Boehringer Ingelheim Investigational Site
Alabama, United States
Birmingham
Cooper Green Hospital
Alabama, United States
Birmingham
University of Alabama at Birmingham
Alabama, United States
Los Angeles
David Geffen School of Medicine
California, United States
Sepulveda
VA Greater Los angeles Health Care Systems
California, United States
Waterbury
Boehringer Ingelheim Investigational Site
Connecticut, United States
WEst Haven
Yale Univ. Pulmonary and Critical Care Medicine
Connecticut, United States
Panama City
Emerald Coast Research Associates
Florida, United States
St. Petersberg
Bay Pines V. A. Medical Center
Florida, United States
New Orleans
Louisiana State University School of Medicine
Louisiana, United States
Shreveport
LSU MC-Sheveport
Louisiana, United States
Bronx
Bronx VA Medical Center
New York, United States
Greenville
Brody School of Medicine, East Carolina University
North Carolina, United States
Philadelphia
Boehringer Ingelheim Investigational Site
Pennsylvania, United States
Philadelphia
Temple University Hospital
Pennsylvania, United States
Charleston
Boehringer Ingelheim Investigational Site
South Carolina, United States
Spartanburg
Spartanburg Medical Research
South Carolina, United States
Houston
Attention: Amir Sharafkhaneh, M.D.
Texas, United States
Houston
VAMC Houston
Texas, United States
Primary Contact(s)
Boehringer Ingelheim
Data obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Learn more at
ClinicalTrials.gov